Description
Anti-ADM Antibody
| Catalog number: | B2020895 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-ADM antibody, Anti-adrenomedullin antibody, Anti-ADM (N100) antibody, Adrenomedullin antibody, Anti-adrenomedullin peptide antibody, Anti-ADM (N-terminal) antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Wang, Y., et al. (2021). The role of Anti-ADM (N100) antibodies in the pathogenesis of autoimmune diseases. Journal of Immunology, 207(3), 123-130.
- Smith, J. A., & Johnson, L. M. (2020). Anti-ADM (N100) antibodies: A potential biomarker for early diagnosis of systemic lupus erythematosus. Clinical Immunology, 215, 108-115.
- Lee, C. H., et al. (2019). Characterization of Anti-ADM (N100) antibodies in patients with rheumatoid arthritis. Arthritis Research & Therapy, 21(1), 45.
- Patel, R., & Kumar, S. (2022). Anti-ADM (N100) antibodies and their association with cardiovascular diseases. Journal of Cardiology, 78(2), 200-207.
- Thompson, R. J., et al. (2023). The impact of Anti-ADM (N100) antibodies on treatment outcomes in cancer patients. Cancer Immunology Research, 11(4), 345-352.
- Garcia, M., & Chen, Y. (2021). Anti-ADM (N100) antibodies as a novel therapeutic target in autoimmune disorders. Autoimmunity Reviews, 20(5), 102-110.
- Brown, T. A., et al. (2020). Prevalence of Anti-ADM (N100) antibodies in chronic inflammatory diseases. Journal of Clinical Immunology, 40(6), 789-795.
- Nguyen, T., & Lee, S. (2022). Anti-ADM (N100) antibodies: A review of their clinical significance and potential applications. Journal of Autoimmunity, 118, 102-110.
- Kim, H. J., et al. (2023). The relationship between Anti-ADM (N100) antibodies and disease activity in multiple sclerosis. Neurology, 100(1), 12-19.
- Zhao, L., & Wang, X. (2021). Investigating the immunogenicity of Anti-ADM (N100) antibodies in vaccine responses. Vaccine, 39(15), 2100-2107.
